Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Aeromics Inc. is managing 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners and 2 distinct art units. This distribution means that each of the active matters is being reviewed by a different examiner in a separate specialized unit, rather than being clustered under a single point of contact.
COUGHLIN, MATTHEW P is the busiest examiner for the portfolio, currently handling 1 pending office action. Because each of the 2 pending actions is assigned to a different examiner and art unit, there is no central point of influence for the portfolio's current prosecution. Practitioners should expect to manage unique examiner relationships and navigate the specific standards of the different art units, requiring an individualized approach to each of the pending matters in the Biotechnology & Pharmaceuticals sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| COUGHLIN, MATTHEW P | 1 | 71.3% | +12.5% |
| ARNOLD, ERNST V | 1 | 48.2% | +12.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18819236 | CRYSTALS | COUGHLIN, MATTHEW P | — |
| 18040618 | PHARMACEUTICAL COMPOSITION OF AQUAPORIN INHIBITOR AND PREPARATION METHOD THEREOF | ARNOLD, ERNST V | — |
| Art Unit | Apps |
|---|---|
| 1626 | 1 |
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18819236 | CRYSTALS | COUGHLIN, MATTHEW P | 1626 | §103§112DP | Non-Final OA | — | Pending | Aug 29, 2024 |
| 18040618 | PHARMACEUTICAL COMPOSITION OF AQUAPORIN INHIBITOR AND PREPARATION METHOD THEREOF | ARNOLD, ERNST V | 1613 | §103§112DP | Non-Final OA | — | Pending | Feb 03, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAeromics Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Matthew P Coughlin has the most, with 1 of Aeromics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
